抗菌薬の世界市場:セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬

◆英語タイトル:Antibacterial Drugs: World Industry and Market Prospects 2016-2026
◆商品コード:VGAIN6041536
◆発行会社(調査会社):visiongain
◆発行日:2016年3月
◆ページ数:300
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Antibacterial Drugs: World Industry and Market Prospects 2016-2026 – our new study reveals trends, R&D progress, and predicted revenuesWhere is the Antibacterial Drugs market heading? Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 300 page report provides 124 tables and 97 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibacterial Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
• Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
• Discusses the dynamic of the antibacterial drugs market and the company’s drug candidate, AIC499 for the treatment of Gram-negative infections.
- Dr Bruce R. Donald (Duke University) Dr Amy C. Anderson (University of Connecticut), Mr. Pablo Gainza-Cirauqui (Duke University)
• Discusses OSPREY, the protein-design algorithm to predict mutation.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other antibiotics.

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those antibacterial drugs?
How will individual antibacterial drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these brands:
• Cephalosporins
- Rocephin
- Sulperazon
- Ceftin/Zinnat
- Meiact
- Flomox
- Teflaro
- Zeftera
- Ceftolozane-tazobactam
- Ceftazidime-Avibactam

• Penicillins
- Generic amoxicillin
- Augmentin
- Zosyn/Tazocin
- Unasyn
- Generic amoxicllin-clavulanic acid
- Amoxil

• Fluoroquinolones
- Avelox
- Cravit
- Vigamox
- Ciprodex
- Cipro/Cirpobay
- Geninax
- Defafloxacin

• Macrolides
- Biaxin/Clarith
- Zithromax
- Dalacin
- Dificid
- Solithromycin

• Carbapenems
- Invanz
- Merrem/Meropen
- Primaxin
- Doribax

• Other antibiotics
- Zyvox
- Cubicin
- Tygacil
- TOBI/TIP
- Solodyn
- Vibativ
- Sirturo
- Tedizolid
- Oritavancin
- Dalbavancin
- Nemonoxacin
- Surotomycin

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).
• South Korea

This chapter also provides incidence of infection and antibacterial drug consumption by country.

Leading companies and the potential for market growth
Our analyses forecasts the world market for antibacterial drug market will reach $44.13bn in 2020.

You can also see which companies hold the most potential:
• Pfizer
• Merck & Co.
• GlaxoSmithKline
• Novartis
• Bayer
• Taisho Pharmaceuticals
• AstraZeneca
• Abbott Labs
• Daiichi Sankyo

【レポートの目次】

1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports

2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market, 2016-2026
3.1 Antibacterials’ Revenues Plateau between 2010 and 2015
3.2 Antibacterial Agents – Market Segmentation
3.3 Antibiotics Market Forecast, 2016-2026: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2016-2026
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2016-2026
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2014
3.8 Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast, 2016-2026
4.1 Cephalosporins Market 2015 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2016 and 2026
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2016 and 2026
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2016-2026
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition – Forecast 2016-2026
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2016-2026
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue – Forecast 2016-2026
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2016-2026
4.1.10 Flomox – Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericisation and Safety to Restrict Sales – Forecast 2016-2026
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2016-2026
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval – Revenue Forecast 2016-2026
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2016-2026
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales – Forecast 2016-2026

5. Penicillins Market Forecast, 2016-2026
5.1 Generics and Augmentin Dominate the Penicillins Market in 2015
5.2 Augmentin to Lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2016-2026
5.3 Penicillin Antibacterials: Market Forecast 2016-2026
5.4 Drivers and Restraints for the Penicillin Market 2016-2026
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2016-2026
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2016-2026
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues – Forecast 2016-2026
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2016-2026
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2016-2026
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2016-2026

6. Fluoroquinolone Market Forecast, 2016-2026
6.1 The Fluoroquinolone Market 2015
6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2016-2026
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2016-2026
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2016-2026
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2016-2026
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2016-2026
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2010-2013
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2016-2026
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2016-2026
6.9.2 Cipro Revenue Forecast 2016-2026: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2016-2026
6.11 Delafloxacin
6.11.1 Revenue Forecast 2016-2026

7. Macrolide Market Forecast, 2016-2026
7.1 Macrolide Market in 2015
7.2 Changing Market Share for Macrolides, 2016-2026
7.3 Macrolide Antibacterials: Market Forecast 2016-2026
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2014
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2016-2026
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2016-2026
7.7 Dalacin
7.7.1 Revenue Forecast 2016-2026
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2016-2026
7.9 Solithromycin
7.9.1 Revenue Forecast 2016-2026

8. Carbapenem Market Forecast, 2016-2026
8.1 Carbapenem Market 2015
8.2 Changing Market Share for Carbapenems, 2016-2026
8.3 Carbapenem Market Forecast, 2016-2026
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2016-2026
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2016-2026
8.7 Invanz
8.7.1 Revenue Forecast 2016-2026
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2016-2026

9. Other Antibiotic Drugs Forecast, 2016-2026
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2016-2026
9.3 Other Antibacterials: Market Forecast, 2016-2026
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2026
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2016-2026
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2020, Revenue Forecast 2016-2026
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2016-2026
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2016-2026
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2016-2026
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2016-2026
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2016-2026
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2016-2026
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2016-2026
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2016-2026
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2016-2026
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2016-2026

10. The Leading National Markets, 2016-2026
10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2016-2026
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2015
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2015
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2016-2026
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2020 to 2026
10.8 Japan – Still the Fourth Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2016-2026
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2016-2026
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2016-2026
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales – Forecast 2016-2026

11. Antibacterials R&D Pipeline Review, 2016
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.2 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.3 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.4 Solithromycin – Fluroketolide with Favourable Side Effect Profile
11.3.5 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.6 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.7 Cadazolid: Largest PIII C. Difficile Trial
11.3.8 Omadacycline – Another Phase III-Ready Partnership
11.3.9 Relebactam – A Novel β-Lactamase Combination
11.3.10 CEM-102 (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.3.11 BC-3781- Unique Mechanism of Action at 23S?
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.3 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.4 TD-1792 – A Russian Antibacterial Medicine
11.4.5 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.6POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE

12. Qualitative Analysis of the Antibacterials Industry and Market, 2016
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand Will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development

13. Research Interviews from Our Survey
13.1 Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
13.1.1 AiCuris Anti-infective Cures GmbH
13.1.2 Introduction
13.1.3 Antibacterial Drugs Market – What Dynamic Have You Observed?
13.1.4 Antibacterial Drugs Market – Drivers and Restraints
13.1.5 What Technological Advances Will Benefit the Antibacterial Drugs Market?
13.1.6 The Burden of Carbapenem-resistant organisms in Germany
13.1.7 AiCuris – Present Development Status of AIC499
13.2 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut), and Mr. Pablo Gainza-Cirauqui (Duke University)
13.2.1 OSPREY
13.2.2 OSPREY – Specializes in Accurate Negative Design
13.2.3 Technical Challenges in Predicting Mutations
13.2.4 Success Rate – Top Four Predictions Confirmed in vitro
13.2.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
13.2.6 Further Work: Optimize Antibody for Highest in vivo Efficacy
13.2.7 Anticipate Mutations – Redesign Drugs to Maximize Effective Lifespan

14. Antibacterial Drugs Market to 2026: Conclusions
14.1 Three Blockbuster Antibacterials in 2015, Leading Brands
14.2 The Leading Branded Antibacterial Drugs in 2026
14.3 Signs of Life in the Antibacterial R&D Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development

Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
Table 2.1 Common Bacterial Infections and Their Causes
Table 2.2 Details of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Diseases Deaths Worldwide, 2010
Table 2.4 Mechanisms of Action for Antibacterial Drugs, 2015
Table 3.1 Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2010-2015
Table 3.2 Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2015
Table 3.3 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
Table 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2015-2026
Table 3.5 Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2014
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
Table 4.2 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2015
Table 4.3 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2020
Table 4.4 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2026
Table 4.5 Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.6 Cephalosporin Market Forecast by Product: Market Share (%), 2015-2026
Table 4.7 Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.8 Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.9 Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.10 Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.11 Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.12 Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
Table 4.13 Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.14 Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.15 Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 4.16 Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.1 Leading Branded Penicillin Drugs: Important Facts
Table 5.2 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2015
Table 5.3 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2020
Table 5.4 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2026
Table 5.5 Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.6 Penicillin Market Forecast by Product: Market Share (%), 2015-2026
Table 5.7 Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.8 Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.11 Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 5.12 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.1 Leading Branded Fluoroquinolone Drugs: Important Facts
Table 6.2 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2015
Table 6.3 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2020
Table 6.4 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2026
Table 6.5 Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.6 Fluoroquinolone Market Forecast by Product: Market Share (%), 2015-2026
Table 6.7 Global Patent Expiration Dates for Avelox
Table 6.8 Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.9 Generic Manufacturers of Levofloxacin, 2015
Table 6.10 Cravit and Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.12 Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.13 Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.14 Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 6.15 Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.1 Leading Branded Macrolides: Important Facts
Table 7.2 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2015
Table 7.3 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2020
Table 7.4 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2026
Table 7.5 Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.6 Macrolide Market Forecast by Product: Market Shares (%), 2015-2026
Table 7.7 Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.8 Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.9 Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.10 Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 7.11 Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 8.1 Leading Branded Carbapenems: Important Facts
Table 8.2 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2015
Table 8.3 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2020
Table 8.4 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2026
Table 8.5 Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 8.6 Carbapenem Market Forecast by Product: Market Share (%), 2015-2026
Table 8.7 Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 8.8 Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 8.9 Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 8.10 Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.1 Other Leading Branded Antibacterials: Important Facts
Table 9.2 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2015
Table 9.3 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2020
Table 9.4 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2026
Table 9.5 Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.6 Other Agents: Market Forecast by Product - Market Share (%), 2015-2026
Table 9.7 Oxazolidinones in Mid to Late Stage Clinical Development, 2015
Table 9.8 Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.9 Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.10 Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.11 TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.12 Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.13 Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.14 Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.15 Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.16 Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.17 Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.18 Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 9.19 Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2015
Table 10.2 Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2015-2026
Table 10.3 Antibacterial Drug Markets: National and Regional Market Shares (%), 2015-2026
Table 10.4 Incidence of Pneumonia in National Markets, 2015
Table 10.5 Incidence of Community Acquired Urinary Tract Infections in National Markets, 2015
Table 10.6 Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2015
Table 10.7 Incidence of Upper Respiratory Tract Infections in National Markets, 2015
Table 10.8 Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2013
Table 10.9 Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2013
Table 10.10 US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.11 EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.12 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.13 French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.15 UK Early Stage Antibacterial Drug Developers, 2015
Table 10.16 UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.17 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.18 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.19 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.20 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.21 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.22 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.23 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 10.24 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2026
Table 11.1 Small Molecule Antibacterial Drug in Phase III Development, 2016
Table 11.2 Small Molecule Antibacterial Drug in Phase II Development, 2016
Table 11.3 Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical Development, 2016
Table 11.4 Biological Antibacterial Therapeutics in Clinical Development, 2016
Table 12.1 Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2016-2026
Table 12.2 Bacterial Related Funding for BARDA, 2011-2014
Table 14.1 World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2014, 2015, 2020 and 2026

List of Figures
Figure 2.1 Leading Causes of Infectious Disease Deaths Worldwide, 2010
Figure 2.2 Key Events in the History of Antibacterial Drug Development
Figure 3.1 Historic Global Market Size ($bn), 2010-2015
Figure 3.2 Global Antibacterial Drug Market by Sector: Market Share (%), 2015
Figure 3.3 Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2016-2026
Figure 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2020
Figure 3.5 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2026
Figure 3.6 Ten Leading Branded Antibacterial Manufacturers: Market Share (%), 2014
Figure 4.1 Cephalosporin Market by Product: Market Share (%), 2015
Figure 4.2 Cephalosporin Market by Product: Market Share (%), 2020
Figure 4.3 Cephalosporin Market by Product: Market Share (%), 2026
Figure 4.4 Cephalosporin Market Forecast: Revenue ($bn), 2016-2026
Figure 4.5 Cephalosporin Market: Drivers and Restraints, 2016-2026
Figure 4.6 Rocephin Forecast: Revenue ($bn), 2016-2026
Figure 4.7 Sulperazon Forecast: Revenue ($bn), 2016-2026
Figure 4.8 Zinnat/Ceftin Forecast: Revenue ($bn), 2016-2026
Figure 4.9 Meiact Forecast: Revenue ($bn), 2016-2026
Figure 4.10 Flomox Forecast: Revenue ($bn), 2016-2026
Figure 4.11 Zinforo/Teflaro Forecast: Revenue ($bn), 2016-2026
Figure 4.12 Zeftera Forecast: Revenue ($bn), 2016-2026
Figure 4.13 Ceftolozane-Tazobactam Forecast: Revenue ($bn), 2016-2026
Figure 4.14 Ceftazidime-Avibactam Forecast: Revenue ($bn), 2016-2026
Figure 5.1 Penicillin Market by Product: Market Share (%), 2015
Figure 5.2 Penicillin Market by Product: Market Share (%), 2020
Figure 5.3 Penicillin Market by Product: Market Share (%), 2026
Figure 5.4 Penicillin Market Forecast: Revenue ($bn), 2016-2026
Figure 5.5 Augmentin Forecast: Revenue ($bn), 2016-2026
Figure 5.6 Zosyn/Tazocin Forecast: Revenue ($bn), 2016-2026
Figure 5.7 Unasyn Forecast: Revenue ($bn), 2016-2026
Figure 5.8 Amoxil Forecast: Revenue ($bn), 2016-2026
Figure 5.9 Generic Amoxicillin Forecast: Revenue ($bn), 2016-2026
Figure 5.10 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2016-2026
Figure 6.1 Fluoroquinolone Market by Product: Market Share (%), 2015
Figure 6.2 Fluoroquinolone Market by Product: Market Share (%), 2020
Figure 6.3 Fluoroquinolone Market by Product: Market Share (%), 2026
Figure 6.4 Fluoroquinolone Market Forecast: Revenue ($bn), 2016-2026
Figure 6.5 Avelox Forecast: Revenue ($bn), 2016-2026
Figure 6.6 Cravit and Levaquin Forecast: Revenue ($bn), 2016-2026
Figure 6.7 Vigamox Forecast: Revenue ($bn), 2016-2026
Figure 6.8 Ciprodex Forecast: Revenue ($bn), 2016-2026
Figure 6.9 Cipro/Ciprobay Forecast: Revenue ($bn), 2016-2026
Figure 6.10 Geninax Forecast: Revenue ($bn), 2016-2026
Figure 6.11 Delafloxacin Forecast: Revenue ($bn), 2016-2026
Figure 7.1 Macrolide Market by Product: Market Share (%), 2015
Figure 7.2 Macrolide Market by Product: Market Share (%), 2020
Figure 7.3 Macrolide Market by Product: Market Share (%), 2026
Figure 7.4 Macrolide Market Forecast: Revenue ($bn), 2016-2026
Figure 7.5 Biaxin/Clarith Forecast: Revenue ($bn), 2016-2026
Figure 7.6 Zithromax Forecast: Revenue ($bn), 2016-2026
Figure 7.7 Dalacin Forecast: Revenue ($bn), 2016-2026
Figure 7.8 Dificid Forecast: Revenue ($bn), 2016-2026
Figure 7.9 Solithromycin Forecast: Revenue ($bn), 2016-2026
Figure 8.1 Carbapenem Market by Product: Market Share (%), 2015
Figure 8.2 Carbapenem Market by Product: Market Share (%), 2020
Figure 8.3 Carbapenem Market by Product: Market Share (%), 2026
Figure 8.4 Carbapenem Market Forecast: Revenue ($bn), 2016-2026
Figure 8.5 Merrem Forecast: Revenue ($bn), 2016-2026
Figure 8.6 Primaxin Forecast: Revenue ($bn), 2016-2026
Figure 8.7 Invanz Forecast: Revenue ($bn), 2016-2026
Figure 8.8 Doribax Forecast: Revenue ($bn), 2016-2026
Figure 9.1 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2015
Figure 9.2 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2020
Figure 9.3 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2026
Figure 9.4 Other Agents Market Forecast by Product: Revenue ($bn), 2016-2026
Figure 9.5 Zyvox Forecast: Revenue ($bn), 2016-2026
Figure 9.6 Cubicin Forecast: Revenue ($bn), 2016-2026
Figure 9.7 Tygacil Forecast: Revenue ($bn), 2016-2026
Figure 9.8 TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2016-2026
Figure 9.9 Solodyn Forecast: Revenue ($bn), 2016-2026
Figure 9.10 Vibativ Forecast: Revenue ($bn), 2016-2026
Figure 9.11 Sirturo Forecast: Revenue ($bn), 2016-2026
Figure 9.12 Tedizolid Forecast: Revenue ($bn), 2016-2026
Figure 9.13 Oritavancin Forecast: Revenue ($bn), 2016-2026
Figure 9.14 Dalbavancin Forecast: Revenue ($bn), 2016-2026
Figure 9.15 Surotomycin Forecast: Revenue ($bn), 2016-2026
Figure 9.16 Nemonoxacin Forecast: Revenue ($bn), 2016-2026
Figure 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Share (%), 2015
Figure 10.2 Antibacterial Drug Market Forecasts: National and Regional Market Sizes ($bn), 2015-2026
Figure 10.3 Absolute Annual Antibacterial Drug Consumption by Nation, 2015
Figure 10.4 Per Capita Antibacterial Drug Consumption by Nation, 2015
Figure 10.5 US Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.6 EU Antibacterial Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2016-2026
Figure 10.7 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.8 French Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.10 UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.11 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.12 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.13 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.14 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), 2016-2026
Figure 10.15 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.16 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.17 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 10.18 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2016-2026
Figure 12.1 Strengths and Weaknesses of the Antibacterial Drug Market, 2016-2026
Figure 12.2 Opportunities and Threats for the Antibacterial Drug Market, 2016-2026
Figure 12.3 Strategies and Technologies to Prevent Hospital Acquired Infections, 2016

【レポートのキーワード】

抗菌薬、抗菌剤、医薬品、セファロスポリン、ペニシリン、フルオロキノロン、マクロライド、カルバペネム

★調査レポート[抗菌薬の世界市場:セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬]販売に関する免責事項
★調査レポート[抗菌薬の世界市場:セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆